Monotherapy with PI3K/AKT/mTOR inhibitors in gynecologic cancers, however, has been shown to have a limited clinical benefit, and no drug is approved by the US FDA in gynecologic cancer currently [110]. This evidence concerns the gene AKT1 and female reproductive organ cancer.